Discover how molecular glues are transforming drug discovery by enabling targeted protein degradation of previously “undruggable” targets. Learn their mechanism, advantages over PROTACs, and emerging AI‑driven design strategies in oncology and immunology.
Discover how NTRX-07, a first-in-class small molecule targeting microglial activity, offers a novel immunology-based strategy for Alzheimer’s disease by reducing neuroinflammation, enhancing amyloid-β clearance, and promoting neuroprotective repair pathways.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.